Close Menu

NEW YORK (GenomeWeb) – Cepheid said yesterday that it will delay the international market launch of its point-of-care platform, the Omni, by one year to the third quarter of 2017.

The firm's stock fell sharply on the news, down more than 19 percent on Nasdaq at mid-day trading following the announcement.

Cepheid first unveiled the Omni in July 2015, when it also announced plans to develop a line of more rapid tests, called Xpert Xpress.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.